Literature DB >> 8534764

Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL.

A Böhme1, A Ganser, D Hoelzer.   

Abstract

In four of 14 patients with acute lymphoblastic leukemia (ALL) who received induction chemotherapy containing weekly injections of vincristine and simultaneous antifungal prophylaxis with itraconazole, unusually severe and early vincristine-induced neurotoxicity was observed. In these patients (three female, one male) paresthesia and muscle weakness of the upper/lower extremities and paralytic ileus occurred after the first or second vincristine injection. In one patient a laryngeal nerve paresis required mechanical ventilation. The neurotoxic complications were more serious than those seen in a previous series of 460 ALL patients under the identical cytostatic regimen but without itraconazole prophylaxis. The underlying mechanism is unclear. Interaction with the cytochrome P-450 system, reversal of multidrug resistance, and influence of estrogens are to be considered.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8534764     DOI: 10.1007/bf01697985

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  9 in total

1.  Safety and efficacy of itraconazole in prevention of fungal infections in neutropenic patients.

Authors:  P L Thunnissen; W Sizoo; W D Hendriks
Journal:  Neth J Med       Date:  1991-08       Impact factor: 1.422

2.  Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies.

Authors:  G Tricot; E Joosten; M A Boogaerts; J Vande Pitte; G Cauwenbergh
Journal:  Rev Infect Dis       Date:  1987 Jan-Feb

Review 3.  Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses.

Authors:  S M Grant; S P Clissold
Journal:  Drugs       Date:  1989-03       Impact factor: 9.546

4.  Treatment of invasive aspergillosis with itraconazole.

Authors:  D W Denning; R M Tucker; L H Hanson; D A Stevens
Journal:  Am J Med       Date:  1989-06       Impact factor: 4.965

5.  Reversal of daunorubicin resistance in P388/ADR cells by itraconazole.

Authors:  S Gupta; J Kim; S Gollapudi
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

Review 6.  Oral azole drugs as systemic antifungal therapy.

Authors:  J A Como; W E Dismukes
Journal:  N Engl J Med       Date:  1994-01-27       Impact factor: 91.245

7.  Itraconazole and multidrug resistance: possible effects on remission rate and disease-free survival in acute leukemia.

Authors:  G Vreugdenhil; J M Raemaekers; B J van Dijke; B E de Pauw
Journal:  Ann Hematol       Date:  1993-09       Impact factor: 3.673

8.  Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions.

Authors:  X R Zhou-Pan; E Sérée; X J Zhou; M Placidi; P Maurel; Y Barra; R Rahmani
Journal:  Cancer Res       Date:  1993-11-01       Impact factor: 12.701

9.  Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study.

Authors:  G Vreugdenhil; B J Van Dijke; J P Donnelly; I R Novakova; J M Raemaekers; M A Hoogkamp-Korstanje; M Koster; B E de Pauw
Journal:  Leuk Lymphoma       Date:  1993-11
  9 in total
  15 in total

Review 1.  Role of itraconazole in haematology/oncology.

Authors:  N A Pandya; A A Atra; U Riley; C R Pinkerton
Journal:  Arch Dis Child       Date:  2003-03       Impact factor: 3.791

Review 2.  Adverse interactions between antifungal azoles and vincristine: review and analysis of cases.

Authors:  Brad Moriyama; Stacey A Henning; Janice Leung; Oluwaseun Falade-Nwulia; Paul Jarosinski; Scott R Penzak; Thomas J Walsh
Journal:  Mycoses       Date:  2011-11-29       Impact factor: 4.377

Review 3.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

Review 4.  Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health.

Authors:  Kirsten K Ness; Saro H Armenian; Nina Kadan-Lottick; James G Gurney
Journal:  Expert Rev Hematol       Date:  2011-04       Impact factor: 2.929

5.  Interaction of common azole antifungals with P glycoprotein.

Authors:  Er-jia Wang; Karen Lew; Christopher N Casciano; Robert P Clement; William W Johnson
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

Review 6.  Adverse effects and drug interactions of medications commonly used in the treatment of adult HIV positive patients.

Authors:  R Heylen; R Miller
Journal:  Genitourin Med       Date:  1996-08

Review 7.  Interactions between antiretrovirals and antineoplastic drug therapy.

Authors:  Tony Antoniou; Alice L Tseng
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 8.  Clinical experience with itraconazole in systemic fungal infections.

Authors:  M Boogaerts; J Maertens
Journal:  Drugs       Date:  2001       Impact factor: 9.546

9.  An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia.

Authors:  W Stock; B Diouf; K R Crews; D Pei; C Cheng; K Laumann; S J Mandrekar; S Luger; A Advani; R M Stone; R A Larson; W E Evans
Journal:  Clin Pharmacol Ther       Date:  2016-11-16       Impact factor: 6.875

10.  Voriconazole and its clinical potential in the prophylaxis of systemic fungal infection in patients with hematologic malignancies: a perspective review.

Authors:  Amaya Zabalza; Ana Gorosquieta; Encarnación Pérez Equiza; Eduardo Olavarria
Journal:  Ther Adv Hematol       Date:  2013-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.